A Phase 2a Open-Label Study Assessing the Effectiveness, Safety, and Tolerability of OralDocarpamine in Patients with Refractory Ascites due to Liver Cirrhosis

Start Date12 May 2020

Sponsor / Collaborator-

100 Clinical Results associated with Docarpamine

100 Translational Medicine associated with Docarpamine

100 Patents (Medical) associated with Docarpamine

Literatures (Medical) associated with Docarpamine

01 Jan 2013·International Heart JournalQ4 · MEDICINE

A Single Center Cross-Sectional Observational Study

Q4 · MEDICINE

Article

Author: Murakami, Daisuke ; Ohba, Takayoshi ; Maruyama, Mitsunori ; Yodogawa, Kenji ; Seino, Yoshihiko ; Mizuno, Kyoichi ; Abe, Junko ; Takano, Masamichi ; Inami, Toru ; Murai, Koji ; Kimata, Nakahisa ; Ibuki, Chikao

The heart failure guideline in Japan has stated the necessity of investigating the role of oral inotropic agents in patients with chronic heart failure (CHF), which are clinically available only in Japan. A total of 1,846 consecutive patients with heart failure (mean: 69.5 years old, 1,279 males) treated at our institute from November 2009 to August 2010 were investigated retrospectively. Thirty-one patients (1.84%) who had taken oral inotropic agents (pimobendan 27, docarpamine 6, and denopamine 4) were extracted for this study, and the efficacy and limitations of the treatments were analyzed. Following the oral inotropic treatment, the NYHA functional class (P = 0.017), cardiothoracic ratio (P = 0.002) and B-type natriuretic peptide levels (P = 0.011) were significantly improved, and the number of emergency room (ER) visits (P < 0.001) and hospitalizations (P < 0.001) were significantly reduced. The nonsurviving patients (n = 7/31, 22.6%) were significantly older (P = 0.02) and tended to have a larger cardiothoracic ratio (P = 0.084) compared with the survivors. An absence of concomitant beta-blocker therapy was significantly associated with a worse prognosis (oneyear mortality 2/21 versus 5/10, log rank, P = 0.011). Oral inotropic agents brought about improvements in the clinical parameters of CHF and a reduction in ER visits and hospitalizations. However, concomitant beta-blocker therapy should be considered for patients receiving oral inotropic treatment.

01 Sep 2009·Journal of Gastroenterology and HepatologyQ3 · MEDICINE

Ascites and spontaneous bacterial peritonitis: An Asian perspective

Q3 · MEDICINE

Review

Author: Kwang Hyub Han ; Jung Min Lee ; Sang Hoon Ahn

AbstractAscites is the most common complication of liver cirrhosis, and it develops as a consequence of portal hypertension and splanchnic vasodilatation. Depending on severity, management of ascites consists of diverse strategy, including dietary sodium restriction, diuretic therapy, repeated large‐volume paracentesis with albumin infusion, transjugular intrahepatic portosystemic shunt, and liver transplantation. Recently, advances in medical therapy have been made with satavaptan, a V2 receptor antagonist, vasoconstrictors, such as clonidine, midodrine, or terlipressin, and other categories of drugs, including docarpamine and Chinese herbs. These drugs may serve as useful adjuncts to conventional diuretics in the management of ascites. Besides ascites itself, serious complications, such as spontaneous bacterial peritonitis (SBP) and hepatorenal syndrome, frequently ensue in decompensated cirrhosis. SBP develops from the translocation of bacteria from the intestine, and successful management with early diagnosis and treatment with proper prevention in patients of high risk is necessary. In summary, ascites is a starting point for more serious complications in liver cirrhosis. Although liver transplantation is the fundamental treatment, it is not always feasible, and consequently various means of treatment should be used. Further study, particularly in Asia where hepatitis B virus‐related cirrhosis is predominant, is warranted to improve the clinical outcome.

01 Mar 2006·Clinical ChemistryQ1 · MEDICINE

Single-Nucleotide Polymorphisms for Diagnosis of Salt-Sensitive Hypertension

Q1 · MEDICINE

Article

Author: Moore, Jason H ; Eisner, Gilbert M ; Ritchie, Marylyn D ; Sasaki, Midori ; Yatabe, Junichi ; Pezzullo, John C ; Hashimoto, Shigeatsu ; Midorikawa, Sanae ; Jose, Pedro A ; Felder, Robin A ; Sanada, Hironobu ; Williams, Scott M ; Watanabe, Tsuyoshi

AbstractBackground: Salt-sensitive (SS) hypertension affects >30 million Americans and is often associated with low plasma renin activity. We tested the diagnostic validity of several candidate genes for SS and low-renin hypertension.Methods: In Japanese patients with newly diagnosed, untreated hypertension (n = 184), we studied polymorphisms in 10 genes, including G protein–coupled receptor kinase type 4 (GRK4), some variations of which are associated with hypertension and impair D1 receptor (D1R)-inhibited renal sodium transport. We used the multifactor dimensionality reduction method to determine the genotype associated with salt sensitivity (≥10% increase in blood pressure with high sodium intake) or low renin. To determine whether the GRK4 genotype is associated with impaired D1R function, we tested the natriuretic effect of docarpamine, a dopamine prodrug, in normotensive individuals with or without GRK4 polymorphisms (n = 18).Results: A genetic model based on GRK4 R65L, GRK4 A142V, and GRK4 A486V was 94.4% predictive of SS hypertension, whereas the single-locus model with only GRK4 A142V was 78.4% predictive, and a 2-locus model of GRK4 A142V and CYP11B2 C-344T was 77.8% predictive of low-renin hypertension. Sodium excretion was inversely related to the number of GRK4 variants in hypertensive persons, and the natriuretic response to dopaminergic stimulation was impaired in normotensive persons having ≥3 GRK4 gene variants.Conclusions: GRK4 gene variants are associated with SS and low-renin hypertension. However, the genetic model predicting SS hypertension is different from the model for low renin, suggesting genetic differences in these 2 phenotypes. Like low-renin testing, screening for GRK4 variants may be a useful diagnostic adjunct for detection of SS hypertension.

100 Deals associated with Docarpamine

External Link

KEGG	Wiki	ATC	Drug Bank
D01903	-	C01CA	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Shock	JP	Mitsubishi Tanabe Pharma Corp.	05 Oct 1994

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis